MalawiTuberculosis profile
Population  2015 17 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.3 (1.3–3.6) 13 (7.7–21)
Mortality (HIV+TB only) 6.6 (3.5–11) 38 (20–62)
Incidence  (includes HIV+TB) 33 (18–53) 193 (104–310)
Incidence (HIV+TB only) 18 (9.4–29) 104 (55–168)
Incidence (MDR/RR-TB)** 0.44 (0.12–0.75) 2.6 (0.7–4.4)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 2 (0.77–3.1) 11 (2.7–19) 13 (3.5–23)
Males 2.2 (1.3–3.1) 18 (11–25) 20 (12–28)
Total 4.1 (2.6–5.6) 29 (19–39) 33 (18–53)
TB case notifications, 2015  
Total cases notified 17 104
Total new and relapse 15 737
          - % tested with rapid diagnostics at time of diagnosis 6%
          - % with known HIV status 93%
          - % pulmonary 75%
          - % bacteriologically confirmed among pulmonary 58%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 47% (29–88)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.29 (0.14–0.55)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 8 408 53%
          - on antiretroviral therapy 7 959 95%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  200
(100–310)
Estimated % of TB cases with MDR/RR-TB 0.75% (0–1.6) 6.4% (3.8–8.9)  
% notified tested for rifampicin resistance <1% 1% 1 088
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 93, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 65, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 85% 16 267
Previously treated cases, excluding relapse, registered in 2014 75% 1 456
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 53% 19
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 79%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
41% (37–45)
TB financing, 2016  
National TB budget (US$ millions) 20
Funding source: 10% domestic, 90% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-06 Data: www.who.int/tb/data